• PDF / 169,516 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 62 Downloads / 230 Views

DOWNLOAD

REPORT

---

1 S

Major and clinically relevant bleeding complications: 8 case reports In a retrospective, controlled study of 308 patients with coronavirus disease 2019 (COVID-19) admitted to hospital in Italy and treated with thromboprophylaxis, 8 patients [ages and sexes not stated] were described, who developed major or clinically relevant bleeding complications during standard thromboprophylactic treatment with enoxaparin-sodium or fondaparinux-sodium [routes, doses and outcome of ADRs not stated]. The patients, who were admitted with non-critically ill COVID-19, started receiving standard thromboprophylactic treatment with enoxaparin-sodium [enoxaparin] once daily (n=1) and fondaparinux-sodium [fondaparinux] once daily. Concomitantly, they were treated with unspecified pharmacological treatment for the infectious disease. However, 8–21 days after initiation of thromboprophylactic treatment, they developed bleeding complications. One patient developed major gastrointestinal bleeding secondary to enoxaparin-sodium (n=1), and 7 patients developed major retroperitoneal bleeding (n=2), major gastrointestinal bleeding (n=2) and clinically relevant non major bleeding in the form of epistaxis (n=3) secondary to fondaparinux-sodium. Therefore, all the patients discontinued the thromboprophylactic therapy. Prandoni P, et al. The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin. Thrombosis Research 196: 803518834 395-397, Dec 2020. Available from: URL: http://doi.org/10.1016/j.thromres.2020.09.024

0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Dec 2020 No. 1833